Developing new antibodies to target a specific protein in cancer cells
Official title: Novel biologic therapeutics targeting vacuolar ATPase localized on plasma membrane
Funded at New York University School of Medicine · NIH-11112635 · Data updated 2026-11-12
This study is working on creating special antibodies that can target a specific protein linked to aggressive cancers caused by the KRAS gene, with the goal of making cancer treatments safer and more effective for patients by reducing side effects on healthy cells.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 21, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $237,724 |
| NIH project number | 1R21CA292032-01A1 |
| Project ID | NIH-11112635 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with KRAS-driven cancers that are difficult to treat with existing therapies.
✕Less likely to help
Patients with cancers not driven by KRAS or those who do not express pmVATPase may not benefit from this research.
What this research studies
This research aims to create novel antibodies that specifically target the plasma membrane vacuolar ATPase (pmVATPase), a protein linked to certain aggressive cancers driven by the KRAS gene. By focusing on pmVATPase, the project seeks to improve the selectivity of cancer treatments, reducing toxicity associated with current therapies that affect normal cell functions. The approach involves understanding the 3D structure of pmVATPase to design effective antibodies that can minimize harm to healthy cells while attacking cancer cells. This innovative method could lead to more effective anti-cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to more targeted and less toxic cancer treatments for patients.
How similar studies have gone: Other research has shown promise in targeting specific proteins in cancer therapy, but this approach focusing on pmVATPase is relatively novel.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Koide, Shohei — New York University School of Medicine
- Study coordinator: Koide, Shohei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.